| Ident. | Authors (with country if any) | Title |
|---|
| 000254 |
Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche] | Milestones in Parkinson's disease therapeutics |
| 000260 |
Rebecca Stowe [Royaume-Uni] ; Natalie Ives [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Kelly Handley [Royaume-Uni] ; Alexandra Furmston [Royaume-Uni] ; Katherine Deane [Royaume-Uni] ; J. J. Van Hilten [Pays-Bas] ; Keith Wheatley [Royaume-Uni] ; Richard Gray [Royaume-Uni] | Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease |
| 000279 |
José Paulo Sousa E Silva ; José S. Lobo ; Maria J. Bonifácio ; Rita Machado ; Amílcar Falcão [Portugal] ; Patrício Soares-Da-Silva | In‐vivo evaluation of prolonged release bilayer tablets of anti‐Parkinson drugs in Göttingen minipigs |
| 000407 |
Daniela Berg [Allemagne] ; Jana Godau [Allemagne] ; Claudia Trenkwalder [Allemagne] ; Karla Eggert [Allemagne] ; Iiona Csoti [Allemagne] ; Alexander Storch [Allemagne] ; Heiko Huber [Allemagne] ; Monica Morelli-Canelo [Allemagne] ; Maria Stamelou [Allemagne] ; Vincent Ries [Allemagne] ; Martin Wolz [Allemagne] ; Christine Schneider [Allemagne] ; Thérèse Di Paolo [Canada] ; Fabrizio Gasparini [Suisse] ; Sam Hariry [Suisse] ; Marc Vandemeulebroecke [Suisse] ; Walid Abi-Saab [Suisse] ; Katy Cooke [Royaume-Uni] ; Donald Johns [Suisse] ; Baltazar Gomez-Mancilla [Suisse] | AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials |
| 000411 |
Kitty K. Wong [Australie] ; Jane E. Alty [Australie] ; Amanda G. Goy [Australie] ; Sanjay Raghav [Australie] ; David C. Reutens [Australie] ; Peter A. Kempster [Australie] | A randomized, double‐blind, placebo‐controlled trial of levetiracetam for dyskinesia in Parkinson's disease |
| 000532 |
Claire L. Tomlinson [Royaume-Uni] ; Rebecca Stowe [Royaume-Uni] ; Smitaa Patel [Royaume-Uni] ; Caroline Rick [Royaume-Uni] ; Richard Gray [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] | Systematic review of levodopa dose equivalency reporting in Parkinson's disease |
| 000600 |
Laura E. Hughes [Royaume-Uni] ; Roger A. Barker [Royaume-Uni] ; Adrian M. Owen [Royaume-Uni] ; James B. Rowe [Royaume-Uni] | Parkinson's disease and healthy aging: Independent and interacting effects on action selection |
| 000603 |
Louisa Clare Johnston [Royaume-Uni] ; Michael John Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Andrew Christopher Mccreary [Pays-Bas] ; Peter Jenner [Royaume-Uni] | Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP‐treated common marmosets |
| 000612 |
Ray L. Watts [États-Unis] ; Kelly E. Lyons [États-Unis] ; Rajesh Pahwa [États-Unis] ; Kapil Sethi [États-Unis] ; Matthew Stern [États-Unis] ; Robert A. Hauser [États-Unis] ; Warren Olanow [États-Unis] ; Alex M. Gray [États-Unis] ; Bryan Adams [États-Unis] ; Nancy L. Earl [États-Unis] | Onset of dyskinesia with adjunct ropinirole prolonged‐release or additional levodopa in early Parkinson's disease |
| 000652 |
Emanuele Cereda [Italie] ; Michela Barichella [Italie] ; Carlo Pedrolli [Italie] ; Gianni Pezzoli [Italie] | Low‐protein and protein‐redistribution diets for Parkinson's disease patients with motor fluctuations: A systematic review |
| 000661 |
Adam Zaidel [Israël] ; Hagai Bergman [Israël] ; Ya'Acov Ritov [Israël] ; Zvi Israel Md [Israël] | Levodopa and subthalamic deep brain stimulation responses are not congruent |
| 000670 |
Janne Gierthmühlen [Allemagne] ; Philipp Arning [Allemagne] ; Andreas Binder [Allemagne] ; Jan Herzog [Allemagne] ; Günther Deuschl [Allemagne] ; Gunnar Wasner [Allemagne] ; Ralf Baron [Allemagne] | Influence of deep brain stimulation and levodopa on sensory signs in Parkinson's disease |
| 000688 |
V. Belcastro [Italie] ; L. Pierguidi [Italie] ; A. Castrioto [Italie] ; C. Menichetti [Italie] ; G. Gorgone [Italie] ; R. Ientile ; F. Pisani [Italie] ; A. Rossi [Italie] ; P. Calabresi [Italie] ; N. Tambasco [Italie] | Hyperhomocysteinemia recurrence in levodopa‐treated Parkinson’s disease patients |
| 000782 |
Suk Yun Kang [États-Unis, Corée du Sud] ; Toshiaki Wasaka [États-Unis] ; Ejaz A. Shamim [États-Unis] ; Sungyoung Auh [États-Unis] ; Yoshino Ueki [États-Unis] ; Grisel J. Lopez [États-Unis] ; Tetsuo Kida [États-Unis] ; Seung-Hyun Jin [États-Unis] ; Nguyet Dang [États-Unis] ; Mark Hallett [États-Unis] | Characteristics of the sequence effect in Parkinson's disease |
| 000847 |
Young Seok Park ; Hae Yoo Kim ; Won Seok Chang ; Phil Hyu Lee [Corée du Sud] ; Young Ho Sohn [Corée du Sud] ; Jin Woo Chang | A Comparison of LEDD and Motor Scores Following STN‐DBS Treatment in Patient with Young Onset vs. Late Onset Parkinson's Disease |
| 000970 |
Luigi M. Romito [Italie] ; Maria Fiorella Contarino [Italie] ; Nicola Vanacore [Italie] ; Anna Rita Bentivoglio [Italie] ; Massimo Scerrati [Italie] ; Alberto Albanese [Italie] | Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: Long‐term observation |
| 000994 |
A. H. Schapira [Royaume-Uni] ; Yves Agid [France] ; P. Barone [Italie] ; P. Jenner [Royaume-Uni] ; M. R. Lemke [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; H. Reichmann [Allemagne] ; E. Tolosa [Espagne] | Perspectives on recent advances in the understanding and treatment of Parkinson’s disease |
| 000A25 |
Sebastian Paus [Allemagne] ; Franziska Gadow [Allemagne] ; Michael Knapp [Allemagne] ; Christine Klein [Allemagne] ; Thomas Klockgether [Allemagne] ; Ullrich Wüllner [Allemagne] | Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism |
| 000A39 |
Michela Barichella [Italie] ; Emanuele Cereda [Italie] ; Gianni Pezzoli [Italie] | Major nutritional issues in the management of Parkinson's disease |
| 000A46 |
Sophie Molloy [Royaume-Uni] ; Thais Minett [Brésil] ; John T. O'Brien [Royaume-Uni] ; Ian G. Mckeith [Royaume-Uni] ; David J. Burn [Royaume-Uni] | Levodopa use and sleep in patients with dementia with Lewy bodies |
| 000A47 |
Robert A. Hauser [États-Unis] ; Peggy Auinger [États-Unis] ; David Oakes [États-Unis] | Levodopa response in early Parkinson's disease |
| 000A48 |
A. H. V. Schapira [Royaume-Uni] ; M. Emre [Turquie] ; P. Jenner [Royaume-Uni] ; Werner Poewe [Autriche] | Levodopa in the treatment of Parkinson’s disease |
| 000A57 |
Michael Niehues [Allemagne] ; Hensel [Allemagne] | In‐vitro interaction of l‐dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability? |
| 000A67 |
Thomas Müller [Allemagne] ; Wilfried Kuhn [Allemagne] | Homocysteine levels after acute levodopa intake in patients with Parkinson's disease |
| 000B01 |
C. Marin [Espagne] ; E. Aguilar [Espagne] ; G. Mengod [Espagne] ; R. Cortés [Espagne] ; J. A. Obeso [Espagne] | Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats |
| 000B04 |
H. Nissinen [Finlande] ; M. Kuoppam Ki [Finlande] ; M. Leinonen [Suède] ; A. H. Schapira [Royaume-Uni] | Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis |
| 000B07 |
Robert A. Hauser [États-Unis] ; Michel Panisset [Canada] ; Giovanni Abbruzzese [Italie] ; Linda Mancione [États-Unis] ; Nalina Dronamraju [États-Unis] ; Algirdas Kakarieka [Suisse] | Double‐blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease |
| 000B08 |
C. G. Bachmann ; A. Zapf [Allemagne] ; E. Brunner [Allemagne] ; C. Trenkwalder | Dopaminergic treatment is associated with decreased body weight in patients with Parkinson’s disease and dyskinesias |
| 000B30 |
D. Nyholm [Suède] ; R. Constantinescu [Suède] ; B. Holmberg [Suède] ; N. Dizdar [Suède] ; H. Askmark [Suède] | Comparison of apomorphine and levodopa infusions in four patients with Parkinson’s disease with symptom fluctuations |
| 000B80 |
Connie Marras [Canada] ; Anthony E. Lang [Canada] ; Shirley W. Eberly [États-Unis] ; David Oakes [États-Unis] ; Stanley Fahn [États-Unis] ; Steven R. Schwid [États-Unis] ; Christopher Hyson [Canada] ; Ira Shoulson [États-Unis] | A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts |
| 000C36 |
Fabrizio Stocchi [Italie] ; Michele Tagliati [États-Unis] ; C. Warren Olanow [États-Unis] | Treatment of levodopa‐induced motor complications |
| 000C45 |
Stanley Fahn [États-Unis] | The history of dopamine and levodopa in the treatment of Parkinson's disease |
| 000C50 |
Anthony H. V. Schapira [Royaume-Uni] | The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease |
| 000C72 |
G. Linazasoro [Espagne] ; J. Kulisevsky [Espagne] ; B. Hernández [Espagne] | Should levodopa dose be reduced when switched to stalevo? |
| 000D09 |
John G. Nutt [États-Unis] | Pharmacokinetics and pharmacodynamics of levodopa |
| 000D33 |
Cory Toth [Canada] ; Martin Sutton Brown [Canada] ; Sarah Furtado [Canada] ; Oksana Suchowersky [Canada] ; Douglas Zochodne [Canada] | Neuropathy as a potential complication of levodopa use in Parkinson's disease |
| 000D54 |
Nir Giladi [Israël] | Medical treatment of freezing of gait |
| 000D61 |
C. Warren Olanow [États-Unis] | Levodopa/dopamine replacement strategies in Parkinson's disease—Future directions |
| 000D62 |
P. Damier [France] ; F. Viallet [France] ; M. Ziegler [France] ; I. Bourdeix [France] ; K. Rerat [France] | Levodopa/DDCI and entacapone is the preferred treatment for Parkinson’s disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort |
| 000D63 |
Kapil Sethi [États-Unis] | Levodopa unresponsive symptoms in Parkinson disease |
| 000D97 |
Aileen K. Ho [Royaume-Uni] ; John L. Bradshaw [Australie] ; Robert Iansek [Australie] | For better or worse: The effect of levodopa on speech in Parkinson's disease |
| 000E57 |
L. Bet [Italie] ; S. R. Bareggi [Italie] ; F. Pacei [Italie] ; G. Bondiolotti [Italie] ; G. Meola [Italie] ; A. H. V. Schapira [Royaume-Uni] | Bimodal administration of entacapone in Parkinson’s disease patients improves motor control |
| 000F33 |
Charlene Hoffman Snyder [États-Unis] ; Charles H. Adler [États-Unis] | The patient with Parkinson’s disease: Part I–Treating the motor symptoms;Part II–Treating the nonmotor symptoms |
| 000F43 |
Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada] | Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa |
| 000F70 |
Vincent Paillé [France] ; Vincent Henry [France] ; Laurent Lescaudron [France] ; Philippe Brachet [France] ; Philippe Damier [France] | Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias |
| 000F89 |
Chen [États-Unis] ; Swope [États-Unis] | Pharmacotherapy for Parkinson's Disease |
| 001027 |
Giovanni Fabbrini [Italie] ; Jonathan M. Brotchie [Canada] ; Francisco Grandas [Espagne] ; Masahiro Nomoto [Japon] ; Christopher G. Goetz [États-Unis] | Levodopa‐induced dyskinesias |
| 001029 |
Radu Constantinescu [États-Unis] ; Irene Richard [États-Unis] ; Roger Kurlan [États-Unis] | Levodopa responsiveness in disorders with parkinsonism: A review of the literature |
| 001066 |
Angelo Antonini [Italie] ; Ioannis U. Isaias [Italie] ; Margherita Canesi [Italie] ; Maurizio Zibetti [Italie] ; Francesca Mancini [Italie] ; Luigi Manfredi [Italie] ; Marco Dal Fante [Italie] ; Leonardo Lopiano [Italie] ; Gianni Pezzoli [Italie] | Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcome |
| 001088 |
John G. Nutt [États-Unis] | Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa? |
| 001169 |
Obering [États-Unis] ; Chen ; Swope [États-Unis] | Update on Apomorphine for the Rapid Treatment of Hypomobility (“Off”) Episodes in Parkinson's Disease |
| 001185 |
Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France] | The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease |
| 001199 |
Michela Barichella [Italie] ; Agnieszka Marczewska [Italie] ; Roberta De Notaris [Italie] ; Antonella Vairo [Italie] ; Cinzia Baldo [Italie] ; Andrea Mauri [Italie] ; Chiara Savardi [Italie] ; Gianni Pezzoli [Italie] | Special low‐protein foods ameliorate postprandial off in patients with advanced Parkinson's disease |
| 001215 |
Omar R. Tumilasci [Argentine] ; M. G. Cers Simo [Argentine] ; Juan E. Belforte [Argentine] ; Federico E. Micheli [Argentine] ; Eduardo E. Benarroch [États-Unis] ; Jorge H. Pazo [Argentine] | Quantitative study of salivary secretion in Parkinson's disease |
| 001217 |
Kazumichi Yamada [Japon] ; Satoshi Goto [Japon] ; Kazuhito Matsuzaki ; Shinji Nagahiro ; Nagako Murase [Japon] ; Hideki Shimazu [Japon] ; Ryuji Kaji [Japon] ; Jun-Ichi Kuratsu [Japon] ; Yukitaka Ushio [Japon] | Psychiatric Symptoms and Subthalamic Nucleus Stimulation in Parkinson's Disease. A Retrospective Study in Our Japanese Patients |
| 001223 |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bédard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa‐induced dyskinesias by a selective NR1A/2B N‐methyl‐D‐aspartate receptor antagonist in parkinsonian monkeys: Implication of preproenkephalin |
| 001235 |
Wolfgang H. Oertel [Allemagne] ; Erik Wolters [Pays-Bas] ; Cristina Sampaio [Portugal] ; Santiago Gimenez-Roldan [Espagne] ; Bruno Bergamasco [Italie] ; Max Dujardin [France] ; Donald G. Grosset [Royaume-Uni] ; Guy Arnold [Allemagne] ; Klaus L. Leenders [Pays-Bas] ; Hans-Peter Hundemer [États-Unis] ; Alberto Lled [États-Unis] ; Andrew Wood [États-Unis] ; Paul Frewer [États-Unis] ; Johannes Schwarz [Allemagne] | Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study |
| 001313 |
Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Roshan Cools [Royaume-Uni] ; Paul Krack [France] ; Valérie Fraix [France] ; Alina Batir [France] ; Stephan Chabardès [France] ; Alim-Louis Benabid [France] ; Trevor W. Robbins [Royaume-Uni] ; Pierre Pollak [France] | Effects of levodopa and subthalamic nucleus stimulation on cognitive and affective functioning in Parkinson's disease |
| 001322 |
Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni] | Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa |
| 001392 |
Mahmoud M. Iravani [Royaume-Uni] ; Sergio Costa [Royaume-Uni] ; Ghassan Al-Bargouthy [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Bai-Yun Zeng [Royaume-Uni] ; Mikko Kuoppam Ki [Royaume-Uni] ; Jose A. Obeso [Espagne] ; Peter Jenner [Royaume-Uni] | Unilateral pallidotomy in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmosets exhibiting levodopa‐induced dyskinesia |
| 001412 |
Mariese A. Hely [Australie] ; John G. L. Morris [Australie] ; Wayne G. J. Reid [Australie] ; Robert Trafficante [Australie] | Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years |
| 001413 |
Francisca Sueli Monte [Brésil] ; Francisco Pereira Da Silva-Júnior [Brésil] ; Pedro Braga-Neto [Brésil] ; Miguel Ngelo Nobre E Souza [Brésil] ; Veralice Meireles Sales De Bruin [Brésil] | Swallowing abnormalities and dyskinesia in Parkinson's disease |
| 001425 |
Melisa Proulx [Canada] ; François P. De Courval [Canada] ; Michael A. Wiseman [Canada] ; Michel Panisset [Canada] | Salivary production in Parkinson's disease |
| 001428 |
Katherine L. Widnell [États-Unis] ; Cynthia Comella [États-Unis] | Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations |
| 001442 |
A H V. Schapira | Present and future drug treatment for Parkinson’s disease |
| 001458 |
C. Warren Olanow [États-Unis] ; Joseph Jankovic [États-Unis] | Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis‐targeted, disease‐modifying strategy |
| 001462 |
Lance A. Smith [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Ghassan Al-Barghouthy [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Mikko Kuoppamaki [Royaume-Uni, États-Unis] ; Warren Olanow [Finlande] ; Peter Jenner [Royaume-Uni] | Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP‐treated drug‐naïve primates |
| 001464 |
Joseph Jankovic [États-Unis] | Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations |
| 001498 |
Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] | Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 |
| 001527 |
J. Eric Ahlskog [États-Unis] | Challenging conventional wisdom: The etiologic role of dopamine oxidative stress in Parkinson's disease |
| 001539 |
Guowei Huang [Canada, République populaire de Chine] ; Magdalena Dragan [Canada] ; David Freeman [Canada] ; John X. Wilson [Canada, États-Unis] | Activation of catechol‐O‐methyltransferase in astrocytes stimulates homocysteine synthesis and export to neurons |
| 001579 |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew Lees (neurologue) [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study |
| 001584 |
Connie Marras [Canada] ; Anthony Lang [Canada] ; Murray Krahn [Canada] ; George Tomlinson [Canada] ; Gary Naglie [Canada] | Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations |
| 001607 |
Padraig E. O'Suilleabhain [États-Unis] ; Teodoro Bottiglieri [États-Unis] ; Richard B. Dewey Jr. [États-Unis] ; Shailja Sharma [États-Unis] ; Ramon Diaz-Arrastia [États-Unis] | Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease |
| 001613 |
C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio [Portugal] ; Fabrizio Stocchi [Italie] | Levodopa in the treatment of Parkinson's disease: Current controversies |
| 001774 |
D J Brooks [Royaume-Uni] ; H. Sagar [Royaume-Uni] | Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study |
| 001789 |
Stanley Fahn [États-Unis] | Description of Parkinson's Disease as a Clinical Syndrome |
| 001801 |
Antje M. Smala [Allemagne] ; E. Annika Spottke [Allemagne] ; Olaf Machat [Allemagne] ; Uwe Siebert [États-Unis] ; Dieter Meyer [Allemagne] ; Rudolf Köhne-Volland [Allemagne] ; Martin Reuther [Allemagne] ; Janeen Duchane [États-Unis] ; Wolfgang H. Oertel [Allemagne] ; Karin B. Berger [Allemagne] ; Richard C. Dodel [Allemagne] | Cabergoline versus levodopa monotherapy: A decision analysis |
| 001822 |
V. S. Kosti ; J. Marinkovi ; M. Svetel ; E. Stefanova ; S. Przedborski [États-Unis] | The effect of stage of Parkinson’s disease at the onset of levodopa therapy on development of motor complications |
| 001898 |
Werner Poewe [Autriche] ; G. Deuschl ; A. Gordin [Finlande] ; E. Kultalahti [Finlande] ; M. Leinonen [Finlande] | Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6‐month randomized placebo‐controlled double‐blind study in Germany and Austria (Celomen study) |
| 001906 |
A. H. V. Schapira | Dopamine agonists and neuroprotection in Parkinson's disease |
| 001926 |
Azi H. Rajput [Canada] ; Mark E. Fenton [Canada] ; Sam Birdi [Canada] ; Rob Macaulay [Canada] ; David George [Canada] ; Bohdar Rozdilsky [Canada] ; Lee C. Ang [Canada] ; Ambikaipakan Senthilselvan [Canada] ; Oleh Hornykiewicz [Autriche] | Clinical–Pathological study of levodopa complications |
| 001931 |
Francesc Valldeoriola [Espagne] ; Manuela Pilleri [Espagne] ; Eduardo Tolosa [Espagne] ; José L. Molinuevo [Espagne] ; Jordi Rumià [Espagne] ; Enric Ferrer [Espagne] | Bilateral subthalamic stimulation monotherapy in advanced Parkinson's disease: Long‐term follow‐up of patients |
| 001A41 |
Takahiro Fukuda [Japon] | Neurotoxicity of MPTP |
| 001A69 |
J. Eric Ahlskog [États-Unis] ; Manfred D. Muenter [États-Unis] | Frequency of levodopa‐related dyskinesias and motor fluctuations as estimated from the cumulative literature |
| 001A71 |
B. Haslinger ; P. Erhard ; N. Ka Mpfe ; H. Boecker ; E. Rummeny ; M. Schwaiger ; B. Conrad ; A. O. Ceballos-Baumann | Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa |
| 001A73 |
D. A. M. C. Van De Vijver [Pays-Bas] ; R. A. C. Roos [Pays-Bas] ; P. A. F. Jansen [Pays-Bas] ; A. J. Porsius [Pays-Bas] ; A. De Boer [Pays-Bas] | Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records |
| 001A90 |
Alberto Albanese [Italie] ; Ubaldo Bonuccelli [Italie] ; Christine Brefel [France] ; K. Ray Chaudhuri [Royaume-Uni] ; Carlo Colosimo [Italie] ; Tobias Eichhorn [Allemagne] ; Eldad Melamed [Israël] ; Pierre Pollak [France] ; Teus Van Laar [Pays-Bas] ; Mario Zappia [Italie] | Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease |
| 001C39 |
Anette Schrag [Royaume-Uni] ; Niall Quinn [Royaume-Uni] | Dyskinesias and motor fluctuations in Parkinson's disease |
| 001C40 |
J. M. Van Kampen [Canada] ; E. G. Mcgeer [Canada] ; A. Jon Stoessl [Canada] | Dopamine transporter function assessed by antisense knockdown in the rat: Protection from dopamine neurotoxicity |
| 001C57 |
Cheryl Waters [États-Unis] | Catechol‐O‐Methyltransferase (COMT) Inhibitors in Parkinson's Disease |
| 001D39 |
H. Przuntek ; B. Conrad [Allemagne] ; J. Dichgans ; P. H. Kraus ; P. Krauseneck ; G. Pergande ; U. Rinne [Finlande] ; K. Schimrigk ; J. Schnitker ; H. P. Vogel [Allemagne] | SELEDO: a 5‐y‐ear long‐term trial on the effect of selegiline in early parkinsonian patients treated with levodopa |
| 001F92 |
V. V. Myllyl [Finlande] ; K. A. Sotaniemi [Finlande] ; P. Hakulinen [Finlande] ; O. M Ki-Lkola [Finlande] ; E. H. Heinonen [Finlande] | Selegiline as the primary treatment of Parkinson's disease — a long‐term double‐blind study |
| 002326 |
J. De Pedro-Cuesta [Suède, Espagne] ; I. J. Petersen ; L. Stawiarz [Suède] ; G. Gudmundsson ; G. Gudmundsson ; J. Almazán [Espagne] ; H. Tulinius [Islande] ; H. Johansson [Suède] | High levodopa use in periodically time‐clustered, Icelandic birth cohorts. A vestige of parkinsonism etiology? |
| 002685 |
A. Friedman [Pologne] ; J. Sienkiewicz [Pologne] | Psychotic complications of long‐term levodopa treatment of Parkinson's disease |
| 002693 |
U. K. Rinne [Finlande] | New strategies in the treatment of early Parkinson's disease |
| 002703 |
A. Lieberman [États-Unis] ; E. Fazzini [États-Unis] | Experience with selegiline and levodopa in advanced Parkinson's disease |
| 002725 |
E. H. Heinonen [Finlande] ; R. Lammintausta [Finlande] | A review of the pharmacology of selegiline |
| 002A15 |
Yasuo Toyokura ; Yoshikuni Mizuno ; Masao Kase ; Itsuro Sobue ; Yoshigoro Kuroiwa ; Hirotaro Narabayashi ; Masanori Uono ; Takao Nakanishi ; Masakuni Kameyama ; Hitoshi Ito ; Yasuo Shimada ; Makoto Iwata | Effects of bromocriptine on Parkinsonism A nation‐wide collaborative double‐blind study |
| 002B91 |
Reijo J. Marttila [Finlande] ; Urpo K. Rinne [Finlande] | Changing epidemiology of Parkinson's disease: Predicted effects of levodopa treatment |
| 002C28 |
V. Kristensen [Danemark] ; M. Olsen [Danemark] ; A. Theilgaard [Danemark] | Levodopa treatment of presenile dementia |
